Pyrrolo[1,2-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders

A compound of Formula I:

• or a pharmaceutically acceptable salt thereof, wherein:
• R1 and R2 each represent independently for each occurrence hydrogen, C1-4 alkyl, C1-4 haloalkyl, C1-4hydroxyalkyl, C1-4 cyanoalkyl, C1-4 alkoxyl, —(C1-4 alkylene)-(2-6 membered heteroalkyl), cyclopropyl, cyano, halogen, hydroxyl, or —N(R4)2;
• R3 represents independently for each occurrence hydrogen, C1-6 alkyl, or C3-6 cycloalkyl;
• R4 represents independently for each occurrence hydrogen, C1-4 alkyl, cyclopropyl, or —C(O)R3;
• R5 represents independently for each occurrence C1-4 alkyl or C3-6 cycloalkyl;
• R6 represents independently for each occurrence C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxyl, cyano, halogen, hydroxyl, or —N(R4)2;
• X1 is a carbonyl-containing linker selected from —C(O)N(H)-ψ, —C(O)N(H)(C1-6 alkylene optionally substituted with C1-4 alkoxyl or C3-6 cycloalkyl)-ψ, —C(O)N(H)(C1-6 haloalkylene)-ψ, —C(O)N(H)(C3-6 cycloalkylene)-ψ, —C(O)N(H)(3-6 membered heterocycloalkylene)-ψ, —C(O)-(3-6 membered heterocycloalkylene containing at least one ring —N(H)— group)-ψ, —C(O)N(H)C(O)-ψ, and —C(O)N(H)C(O)(C1-6 alkylene)-ψ;
• where ψ is a bond to A1;
• A1 is one of the following:
• a cyclic group selected from a 3-14 membered saturated carbocyclyl, a 5-14 membered partially unsaturated carbocyclyl, a 3-16 membered heterocyclyl, or phenyl;
• each of which is substituted by 0, 1, or 2 occurrences of Y1 and 0, 1, 2, or 3 occurrences of Y2;
• or
• C1-8 alkyl or C2-6 alkynyl;
• A2 is one of the following:
• a cyclic group selected from a 5-12 membered heterocyclyl, 5-10 membered cycloalkyl, or phenyl;
• each of which is optionally substituted by 1, 2, or 3 substituents independently selected from the group consisting of C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxyl, C3-5 cycloalkyl, cyano, halogen, hydroxyl, —N(R4)2, —C(O)N(R4)2, and heteroaryl;
• —N(R4)(3-10 membered heterocycloalkyl or C3-10 cycloalkyl, each optionally substituted by 1, 2, or 3 R6 groups) or —O-(3-10 membered heterocycloalkyl or C3-10 cycloalkyl, each optionally substituted by 1, 2, or 3 R6 groups);
• or
• —(O)N(R4)(aryl or heteroaryl);
• Y1 represents, independently for each occurrence, one of the following:
• 2-8 membered heteroalkyl optionally substituted by a 6-10 membered aryl, a 3-10 membered heterocyclyl, or C3-6 halocycloalkyl;
• 3-10 membered heterocyclyl, 6-10 membered aryl, C3-7 cycloalkyl, —O—C3-6 cycloalkyl, —O-(3-6 membered heterocyclyl), —O-(6-10 membered aryl), or —O—(C2-6 alkynyl);
• or
• C2-6 alkynyl, —C≡C—(C1-6 alkylene)-OR4, —C≡C—(C1-6 alkylene)-N(R3)2, —(C2-4 alkynylene)-(5-6 membered heteroaryl), or C2-6 alkenyl;
• Y2 represents, independently for each occurrence, C1-6 alkyl, C3-6 cycloalkyl, halogen, C1-6 haloalkyl, C1-6hydroxyalkyl, hydroxyl, C1-6 alkoxyl, —O—(C1-8 haloalkyl), cyano, azido, —N(R3)2, —(C1-6 alkylene)-(5-6 membered heterocyclyl), —(C1-6 alkylene)-CO2R3, —CO2R3, —C(O)R5, —S(O)2R5, —C(O)N(R5)2, —C(O)N(R3)2, or C1-6haloalkyl-substituted C3-6 cycloalkyl;
• m is 1 or 2;
• and
• n is 1, 2, or 3.